reboxetine has been researched along with Depressive Disorder, Major in 60 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (1.67) | 18.2507 |
| 2000's | 46 (76.67) | 29.6817 |
| 2010's | 12 (20.00) | 24.3611 |
| 2020's | 1 (1.67) | 2.80 |
| Authors | Studies |
|---|---|
| Hatano, M; Ikuta, T; Iwata, N; Kishi, T; Matsuda, Y; Okuya, M; Sakuma, K | 1 |
| Arumugham, SS; Bond, DJ; Dhanoa, T; Ding, YS; Lam, RW; Puyat, JH; Sossi, V; Vafai, N; Yatham, LN | 1 |
| Callado, LF; Díez-Alarcia, R; González-Maeso, J; Meana, JJ; Miranda-Azpiazu, P; Morentin, B; Muguruza, C | 1 |
| Caudill, MM; Cook, IA; Hunter, AM; Leuchter, AF | 1 |
| Aydin, A; Gulec, M; Ozcan, H; Yucel, A; Yucel, N | 1 |
| Cao, YJ; Hendrix, CW; Kaplin, AI; Rahn, KA | 1 |
| Baghai, TC; Laenger, A; Leicht, G; Lindhaus, S; Rupprecht, R; Schule, C | 1 |
| Bayindirli, D; Caykoylu, A; Deniz, O; Ekinci, O; Kuloglu, M; Vural, G | 1 |
| Anderson, IM; Bell, D; Gutting, P; Harmer, C; Healy, D; Tranter, R | 1 |
| Alamo, C; Camarasa, X; García-García, P; López-Muñoz, F; Pardo, A; Seguí, J | 1 |
| Linka, T; Müller, BW; Sartory, G; Wiltfang, J | 1 |
| Akkaya, C; Cangur, S; Eker, SS; Kirli, S; Sarandol, A | 1 |
| Cohen, A; Cooper-Kazaz, R; Lerer, B | 1 |
| Eyding, D; Gerken, M; Grouven, U; Härter, M; Kaiser, T; Kerekes, MF; Kromp, M; Lelgemann, M; Wieseler, B | 1 |
| Kaiser, T; McGauran, N; Wieseler, B | 1 |
| Jacques, D; Janne, P; Reynaert, C; Tordeurs, D; Zdanowicz, N | 1 |
| Arolt, V; Cerovecki, A; Dehning, S; Müller, N; Musil, R; Riedel, M; Schwarz, MJ; Spellmann, I | 1 |
| Mendels, J; Schwartz, GE; Stahl, SM | 1 |
| Andreoli, V; Caillard, V; Deo, RS; Rybakowski, JK; Versiani, M | 1 |
| Agelink, MW; Baumann, B; Majewski, T; Strum, S; Ullrich, H | 1 |
| Ferguson, JM; Montgomery, S; Schwartz, GE | 1 |
| Fava, M; McGrath, PJ; Sheu, WP | 1 |
| Elger, CE; Falkai, P; Kühn, KU; Maier, W; Quednow, BB; Thiel, M | 1 |
| Hoenig, K; Kühn, KU; Maier, W; Quednow, BB; Stelzenmuelle, R; Wagner, M | 1 |
| Alamo, C; López-Muñoz, F; Rubio, G; San, L | 1 |
| Frodl, T; Hegerl, U; Henkel, V; Juckel, G; Mergl, R; Müller-Siecheneder, F; Pogarell, O | 1 |
| Arolt, V; Erfurth, A; Evers, S; Hetzel, G; Moeller, O; Ponath, G; Rothermundt, M | 1 |
| Preskorn, SH | 1 |
| Held, K; Kuenzel, HE; Murck, H; Steiger, A; Ziegenbein, M | 1 |
| Arolt, V; Erfurth, A; Evers, S; Hetzel, G; Michael, N; Moeller, O; Rothermundt, M | 1 |
| Künzel, HE; Pollmächer, T; Schuld, A | 1 |
| Camarasa, X; Duboc, A; Khazaal, Y; Lopez-Martinez, E; Zullino, DF | 1 |
| Arolt, V; Erfurth, A; Hetzel, G; Michael, N; Moeller, O; Rothermundt, M | 1 |
| Almási, J; Rihmer, Z | 1 |
| Bender, S; Gastpar, M; Linka, T; Müller, BW; Sartory, G | 1 |
| Bandinelli, PL; Polselli, GM | 1 |
| Baldwin, D; Bridgman, K; Buis, C | 1 |
| Amore, M; Di Sarro, R; Gallassi, R; Morreale, A | 1 |
| Millan, MJ | 1 |
| Abrams, M; Cook, I; Leuchter, AF; Moses, T | 1 |
| Agren, H; Bodlund, O; Langworth, S | 1 |
| Baghai, TC; Buechs, R; Eser, D; Jordan, M; Rupprecht, R; Schüle, C; Zwanzger, P | 1 |
| Akgoz, S; Akkaya, C; Kirli, S; Sarandol, A; Saygin Eker, S; Yazicioglu, B | 1 |
| Akgoz, S; Akkaya, C; Eker, SS; Kirli, S; Sivrioglu, EY | 1 |
| Brunnmeier, M; Hegerl, U; Juckel, G; Karch, S; Leicht, G; Mergl, R; Möller, HJ; Mulert, C; Pogarell, O | 1 |
| Akkaya, C; Eker, SS; Kirli, S; Sarandol, A; Sivrioglu, EY; Topaloglu, VC | 1 |
| Alamo, C; García-García, P; López-Muñoz, F; Pardo, A; Rubio, G | 1 |
| Kasper, S; Möller, HJ; Nelson, JC; Papakostas, GI | 1 |
| Augustin, H; Frodl, T; Hegerl, U; Juckel, G; Mavrogiorgou, P; Mulert, C; Müller-Siecheneder, F; Pogarell, O | 1 |
| Burrows, G; Jefferys, D | 1 |
| Arolt, V; Domschke, K; Hetzel, G; Koelkebeck, K; Lang, D; Zwanzger, P | 1 |
| Akkaya, C; Cangur, S; Eker, SS; Kirli, S; Sarandol, A; Sarandol, E | 1 |
| Gallwitz, T; Kirch, MH; Messer, T; Rottach, KG; Schaner, BM; Teufel, LM; Zivotofsky, AZ | 1 |
| Abati, A; Andreoli, V; Carbognin, G; Vantini, G | 1 |
| Amin, M; Chouinard, G; Versiani, M | 1 |
| Tanum, L | 1 |
| Healy, D | 1 |
| Chue, P | 1 |
| Benazzi, F | 1 |
| Kasper, S | 1 |
9 review(s) available for reboxetine and Depressive Disorder, Major
| Article | Year |
|---|---|
Antidepressants for the treatment of adults with major depressive disorder in the maintenance phase: a systematic review and network meta-analysis.
Topics: Adult; Amitriptyline; Antidepressive Agents; Citalopram; Depressive Disorder, Major; Desvenlafaxine Succinate; Duloxetine Hydrochloride; Female; Fluoxetine; Fluvoxamine; Humans; Mirtazapine; Network Meta-Analysis; Paroxetine; Randomized Controlled Trials as Topic; Reboxetine; Sertraline; Venlafaxine Hydrochloride; Vortioxetine | 2023 |
Reboxetine for acute treatment of major depression: systematic review and meta-analysis of published and unpublished placebo and selective serotonin reuptake inhibitor controlled trials.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Double-Blind Method; Humans; Morpholines; Publication Bias; Randomized Controlled Trials as Topic; Reboxetine; Selective Serotonin Reuptake Inhibitors; Treatment Outcome | 2010 |
Effects of reboxetine on anxiety, agitation, and insomnia: results of a pooled evaluation of randomized clinical trials.
Topics: Adult; Antidepressive Agents; Anxiety; Confidence Intervals; Depressive Disorder, Major; Female; Humans; Male; Middle Aged; Morpholines; Psychomotor Agitation; Randomized Controlled Trials as Topic; Reboxetine; Sleep Initiation and Maintenance Disorders | 2002 |
Reboxetine: a norepinephrine selective reuptake pump inhibitor.
Topics: Adrenergic Uptake Inhibitors; Animals; Antidepressive Agents; Biological Availability; Clinical Trials as Topic; Cyclopropanes; Depressive Disorder, Major; Drug Approval; Duloxetine Hydrochloride; Humans; Metabolic Clearance Rate; Milnacipran; Morpholines; Reboxetine; Thiazepines; Thiophenes; United States | 2004 |
[Review of antidepressants from the TCAs to the third generation drugs].
Topics: Antidepressive Agents; Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; Bupropion; Cyclohexanols; Cyclopropanes; Depressive Disorder, Major; Drug Combinations; Duloxetine Hydrochloride; Humans; Mianserin; Milnacipran; Mirtazapine; Monoamine Oxidase Inhibitors; Morpholines; Piperazines; Pyrimidines; Reboxetine; Selective Serotonin Reuptake Inhibitors; Thiophenes; Trazodone; Triazoles; Venlafaxine Hydrochloride | 2004 |
Multi-target strategies for the improved treatment of depressive states: Conceptual foundations and neuronal substrates, drug discovery and therapeutic application.
Topics: Adrenergic Uptake Inhibitors; Animals; Antidepressive Agents; Brain; Bupropion; Clinical Trials as Topic; Cyclohexanols; Depressive Disorder, Major; Dopamine; Dopamine Uptake Inhibitors; Drug Delivery Systems; Drug Design; Drug Therapy, Combination; Humans; Morpholines; Nerve Net; Neurons; Norepinephrine; Reboxetine; Selective Serotonin Reuptake Inhibitors; Serotonin; Venlafaxine Hydrochloride | 2006 |
A meta-analysis of clinical trials comparing reboxetine, a norepinephrine reuptake inhibitor, with selective serotonin reuptake inhibitors for the treatment of major depressive disorder.
Topics: Adrenergic Uptake Inhibitors; Depressive Disorder, Major; Double-Blind Method; Female; Humans; Male; Morpholines; PubMed; Randomized Controlled Trials as Topic; Reboxetine; Selective Serotonin Reuptake Inhibitors; Treatment Outcome | 2008 |
Reboxetine: tolerability and safety profile in patients with major depression.
Topics: Adrenergic Uptake Inhibitors; Age Factors; Antidepressive Agents; Cytochrome P-450 Enzyme System; Depressive Disorder, Major; Drug Interactions; Fluoxetine; Humans; Imipramine; Morpholines; Multicenter Studies as Topic; Randomized Controlled Trials as Topic; Reboxetine; Therapeutic Equivalency | 2000 |
Reboxetine: its effects as measured by the Social Adaptation Self-evaluation Scale.
Topics: Adrenergic Uptake Inhibitors; Adult; Antidepressive Agents; Depressive Disorder, Major; Female; Fluoxetine; Humans; Male; Middle Aged; Morpholines; Multicenter Studies as Topic; Psychiatric Status Rating Scales; Randomized Controlled Trials as Topic; Reboxetine; Selective Serotonin Reuptake Inhibitors; Social Adjustment; Therapeutic Equivalency; Treatment Outcome | 2000 |
25 trial(s) available for reboxetine and Depressive Disorder, Major
| Article | Year |
|---|---|
The Antidepressant Treatment Response Index as a Predictor of Reboxetine Treatment Outcome in Major Depressive Disorder.
Topics: Adult; Antidepressive Agents; Biomarkers; Depressive Disorder, Major; Electroencephalography; Female; Humans; Male; Middle Aged; Morpholines; Predictive Value of Tests; Reboxetine; Single-Blind Method; Treatment Outcome | 2015 |
The effect of serotonergic and noradrenergic antidepressants on face emotion processing in depressed patients.
Topics: Adrenergic Uptake Inhibitors; Adult; Antidepressive Agents; Citalopram; Depressive Disorder, Major; Emotions; Facial Expression; Female; Follow-Up Studies; Humans; Male; Middle Aged; Morpholines; Pattern Recognition, Visual; Reboxetine; Recognition, Psychology; Selective Serotonin Reuptake Inhibitors; Treatment Outcome | 2009 |
Effects of adjunctive reboxetine in patients with duloxetine-resistant depression: a 12-week prospective study.
Topics: Adolescent; Adrenergic Uptake Inhibitors; Adult; Aged; Antidepressive Agents; Depressive Disorder, Major; Drug Resistance; Drug Therapy, Combination; Duloxetine Hydrochloride; Female; Humans; Male; Middle Aged; Morpholines; Psychiatric Status Rating Scales; Reboxetine; Selective Serotonin Reuptake Inhibitors; Thiophenes; Time Factors; Treatment Outcome; Young Adult | 2010 |
Elevated macrophage migration inhibitory factor and decreased transforming growth factor-beta levels in major depression--no influence of celecoxib treatment.
Topics: Adult; Aged; Antidepressive Agents; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Depression; Depressive Disorder; Depressive Disorder, Major; Drug Therapy, Combination; Enzyme-Linked Immunosorbent Assay; Female; Humans; Intramolecular Oxidoreductases; Macrophage Migration-Inhibitory Factors; Male; Middle Aged; Morpholines; Psychiatric Status Rating Scales; Psychological Tests; Pyrazoles; Reboxetine; Sulfonamides; Transforming Growth Factor beta; Young Adult | 2011 |
Reboxetine, a new noradrenaline selective antidepressant, is at least as effective as fluoxetine in the treatment of depression.
Topics: Adrenergic Uptake Inhibitors; Adult; Analysis of Variance; Antidepressive Agents; Chi-Square Distribution; Confidence Intervals; Depressive Disorder, Major; Double-Blind Method; Female; Fluoxetine; Humans; Male; Middle Aged; Morpholines; Prospective Studies; Psychiatric Status Rating Scales; Reboxetine; Selective Serotonin Reuptake Inhibitors | 2002 |
The antidepressant efficacy of reboxetine in patients with severe depression.
Topics: Adrenergic Uptake Inhibitors; Adult; Antidepressive Agents; Depressive Disorder, Major; Double-Blind Method; Female; Humans; Male; Middle Aged; Morpholines; Psychiatric Status Rating Scales; Reboxetine | 2003 |
Switching to reboxetine: an efficacy and safety study in patients with major depressive disorder unresponsive to fluoxetine.
Topics: Adolescent; Adult; Aged; Antidepressive Agents; Depressive Disorder, Major; Drug Resistance; Female; Fluoxetine; Humans; Male; Middle Aged; Morpholines; Psychiatric Status Rating Scales; Reboxetine; Social Behavior | 2003 |
Antidepressive treatment in patients with temporal lobe epilepsy and major depression: a prospective study with three different antidepressants.
Topics: Adult; Aged; Analysis of Variance; Anticonvulsants; Antidepressive Agents; Chi-Square Distribution; Citalopram; Demography; Depressive Disorder, Major; Diagnostic and Statistical Manual of Mental Disorders; Drug Interactions; Electroencephalography; Epilepsy, Temporal Lobe; Female; Humans; Male; Mianserin; Middle Aged; Mirtazapine; Morpholines; Patient Dropouts; Personality Inventory; Prospective Studies; Psychiatric Status Rating Scales; Reboxetine; Time Factors | 2003 |
Effects of serotonergic and noradrenergic antidepressants on auditory startle response in patients with major depression.
Topics: Acoustic Stimulation; Adrenergic Uptake Inhibitors; Adult; Antidepressive Agents, Second-Generation; Depressive Disorder, Major; Electrodes; Female; Habituation, Psychophysiologic; Humans; Male; Middle Aged; Morpholines; Psychiatric Status Rating Scales; Reboxetine; Reflex, Startle; Selective Serotonin Reuptake Inhibitors; Sertraline | 2004 |
Reboxetine adjunct for partial or nonresponders to antidepressant treatment.
Topics: Adult; Antidepressive Agents; Cyclohexanols; Depressive Disorder; Depressive Disorder, Major; Drug Resistance; Drug Therapy, Combination; Dysthymic Disorder; Female; Humans; Male; Mianserin; Middle Aged; Mirtazapine; Morpholines; Personality Inventory; Prospective Studies; Reboxetine; Selective Serotonin Reuptake Inhibitors; Treatment Outcome; Venlafaxine Hydrochloride | 2004 |
The astroglial protein S100B and visually evoked event-related potentials before and after antidepressant treatment.
Topics: Adrenergic Uptake Inhibitors; Adult; Antidepressive Agents; Astrocytes; Citalopram; Depressive Disorder, Major; Electroencephalography; Evoked Potentials, Visual; Female; Humans; Male; Middle Aged; Morpholines; Nerve Growth Factors; Neurons; Personality Inventory; Psychometrics; Reaction Time; Reboxetine; S100 Calcium Binding Protein beta Subunit; S100 Proteins; Selective Serotonin Reuptake Inhibitors; Signal Processing, Computer-Assisted; Statistics as Topic | 2005 |
Reboxetine induces similar sleep-EEG changes like SSRI's in patients with depression.
Topics: Adrenergic Uptake Inhibitors; Adult; Aged; Depressive Disorder, Major; Electroencephalography; Female; Fluoxetine; Humans; Male; Middle Aged; Morpholines; Reboxetine; Selective Serotonin Reuptake Inhibitors; Sleep Initiation and Maintenance Disorders; Sleep Stages; Wakefulness | 2004 |
The impact of the selective monoamine reuptake inhibitors reboxetine and citalopram on visually-evoked event-related potentials in depressed patients.
Topics: Adolescent; Adrenergic Uptake Inhibitors; Adult; Citalopram; Depressive Disorder, Major; Electrooculography; Evoked Potentials, Visual; Female; Humans; Male; Middle Aged; Morpholines; Prospective Studies; Reboxetine; Selective Serotonin Reuptake Inhibitors | 2004 |
Escitalopram/reboxetine combination in depressed patients with substance use disorder.
Topics: Adult; Alcoholism; Antidepressive Agents; Bipolar Disorder; Citalopram; Depressive Disorder, Major; Diagnosis, Dual (Psychiatry); Drug Combinations; Female; Humans; Morpholines; Psychiatric Status Rating Scales; Reboxetine; Substance-Related Disorders | 2005 |
Basal prolactin values correlate with response to reboxetine treatment in major depression, but not with response to citalopram.
Topics: Adrenergic Uptake Inhibitors; Adult; Antidepressive Agents; Citalopram; Depressive Disorder, Major; Female; Humans; Male; Middle Aged; Morpholines; Prolactin; Psychiatric Status Rating Scales; Reboxetine; Selective Serotonin Reuptake Inhibitors | 2005 |
Resolution of sexual dysfunction during double-blind treatment of major depression with reboxetine or paroxetine.
Topics: Adult; Antidepressive Agents, Second-Generation; Depressive Disorder, Major; Double-Blind Method; Female; Humans; Male; Middle Aged; Morpholines; Paroxetine; Psychiatric Status Rating Scales; Reboxetine; Sexual Behavior; Sexual Dysfunctions, Psychological | 2006 |
Memory impairment in patients with late-onset major depression: the effect of antidepressant therapy.
Topics: Adolescent; Adult; Age of Onset; Depressive Disorder, Major; Female; Fluoxetine; Humans; Male; Memory Disorders; Middle Aged; Morpholines; Neuropsychological Tests; Reboxetine; Selective Serotonin Reuptake Inhibitors; Severity of Illness Index | 2006 |
Does the clinical course of depression determine improvement in symptoms and quality of life?
Topics: Adult; Age of Onset; Antidepressive Agents; Depressive Disorder, Major; Female; Health Status; Humans; Life Change Events; Male; Morpholines; Multivariate Analysis; Probability; Psychiatric Status Rating Scales; Quality of Life; Reboxetine; Single-Blind Method; Surveys and Questionnaires; Time Factors; Treatment Outcome | 2006 |
Efficacy and tolerability of reboxetine compared with citalopram: a double-blind study in patients with major depressive disorder.
Topics: Adolescent; Adult; Aged; Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; Citalopram; Depressive Disorder, Major; Double-Blind Method; Drug Administration Schedule; Female; Humans; Male; Middle Aged; Morpholines; Patient Dropouts; Psychiatric Status Rating Scales; Reboxetine; Sexual Dysfunction, Physiological; Xerostomia | 2006 |
Time course of hypothalamic-pituitary-adrenocortical axis activity during treatment with reboxetine and mirtazapine in depressed patients.
Topics: Adrenocorticotropic Hormone; Adult; Aged; Antidepressive Agents; Corticotropin-Releasing Hormone; Depressive Disorder, Major; Dexamethasone; Female; Glucocorticoids; Humans; Hydrocortisone; Hypothalamo-Hypophyseal System; Male; Mianserin; Middle Aged; Mirtazapine; Morpholines; Pituitary-Adrenal System; Psychiatric Status Rating Scales; Reboxetine; Time Factors | 2006 |
A comparison of the efficacy and tolerability of reboxetine and sertraline versus venlafaxine in major depressive disorder: a randomized, open-labeled clinical trial.
Topics: Adolescent; Adrenergic Uptake Inhibitors; Adult; Aged; Cyclohexanols; Depressive Disorder, Major; Drug Evaluation; Drug Interactions; Female; Humans; Male; Middle Aged; Morpholines; Reboxetine; Selective Serotonin Reuptake Inhibitors; Sertraline; Time Factors; Venlafaxine Hydrochloride | 2006 |
Comparison of efficacy and tolerability of reboxetine and venlafaxine XR in major depression and major depression with anxiety features: an open label study.
Topics: Adolescent; Adult; Aged; Antidepressive Agents; Anxiety; Cyclohexanols; Delayed-Action Preparations; Depressive Disorder, Major; Drug Administration Schedule; Drug Evaluation; Female; Follow-Up Studies; Humans; Male; Middle Aged; Morpholines; Psychiatric Status Rating Scales; Reboxetine; Severity of Illness Index; Time Factors; Treatment Outcome; Venlafaxine Hydrochloride | 2006 |
Differential prediction of first clinical response to serotonergic and noradrenergic antidepressants using the loudness dependence of auditory evoked potentials in patients with major depressive disorder.
Topics: Adrenergic Uptake Inhibitors; Adult; Analysis of Variance; Antipsychotic Agents; Citalopram; Depressive Disorder, Major; Drug Therapy, Combination; Evoked Potentials, Auditory; Female; Humans; Male; Morpholines; Prospective Studies; Reboxetine; Selective Serotonin Reuptake Inhibitors; Treatment Outcome | 2007 |
Effects of various antidepressants on serum thyroid hormone levels in patients with major depressive disorder.
Topics: Adolescent; Adrenergic Uptake Inhibitors; Adult; Aged; Antidepressive Agents; Cyclohexanols; Depressive Disorder, Major; Female; Humans; Male; Middle Aged; Morpholines; Psychiatric Status Rating Scales; Reboxetine; Selective Serotonin Reuptake Inhibitors; Thyroid Hormones; Venlafaxine Hydrochloride | 2008 |
Double-blind, placebo-controlled study with reboxetine in inpatients with severe major depressive disorder.
Topics: Adolescent; Adult; Affect; Aged; Analysis of Variance; Antidepressive Agents; Depressive Disorder, Major; Double-Blind Method; Female; Humans; Male; Middle Aged; Morpholines; Placebos; Psychiatric Status Rating Scales; Reboxetine | 2000 |
26 other study(ies) available for reboxetine and Depressive Disorder, Major
| Article | Year |
|---|---|
A Positron Emission Tomography Study of Norepinephrine Transporter Occupancy and Its Correlation with Symptom Response in Depressed Patients Treated with Quetiapine XR.
Topics: Adrenergic Uptake Inhibitors; Adult; Antidepressive Agents; Bipolar Disorder; Delayed-Action Preparations; Depressive Disorder, Major; Dibenzothiazepines; Female; Humans; Hypothalamus; Locus Coeruleus; Male; Middle Aged; Norepinephrine Plasma Membrane Transport Proteins; Positron-Emission Tomography; Quetiapine Fumarate; Reboxetine; Young Adult | 2018 |
Evaluation of 5-HT2A and mGlu2/3 receptors in postmortem prefrontal cortex of subjects with major depressive disorder: effect of antidepressant treatment.
Topics: Amino Acids; Animals; Antidepressive Agents; Citalopram; Depressive Disorder, Major; Down-Regulation; Female; Humans; Ketanserin; Male; Mianserin; Middle Aged; Mirtazapine; Morpholines; Prefrontal Cortex; Radioligand Assay; Rats, Sprague-Dawley; Reboxetine; Receptor, Serotonin, 5-HT2A; Receptors, Metabotropic Glutamate; RNA, Messenger; Tritium; Xanthenes | 2014 |
Fluoxetine associated with thrombocytopenia and treatment with reboxetine: 3 cases.
Topics: Adult; Antidepressive Agents; Antidepressive Agents, Second-Generation; Depressive Disorder, Major; Drug Substitution; Female; Fluoxetine; Humans; Male; Morpholines; Reboxetine; Thrombocytopenia | 2015 |
The role of 5-HT1A receptors in mediating acute negative effects of antidepressants: implications in pediatric depression.
Topics: Adrenergic Uptake Inhibitors; Animals; Antidepressive Agents; Anxiety; Behavior, Animal; Child; Depressive Disorder, Major; Fluoxetine; Humans; Mice; Morpholines; Piperazines; Pyridines; Reboxetine; Receptor, Serotonin, 5-HT1A; Selective Serotonin Reuptake Inhibitors; Serotonin 5-HT1 Receptor Antagonists; Suicidal Ideation; Suicide | 2015 |
Electroconvulsive therapy in a patient with concomitant depression and charcot-marie-tooth disease.
Topics: Aged; Charcot-Marie-Tooth Disease; Combined Modality Therapy; Comorbidity; Contraindications; Depressive Disorder, Major; Electroconvulsive Therapy; Humans; Male; Morpholines; Personality Inventory; Reboxetine; Risperidone; Treatment Outcome | 2008 |
Successful management of depression with reboxetine in a patient who developed Parkinsonism related to paroxetine use.
Topics: Adrenergic Uptake Inhibitors; Antidepressive Agents, Second-Generation; Depressive Disorder, Major; Humans; Male; Middle Aged; Morpholines; Parkinson Disease, Secondary; Paroxetine; Psychiatric Status Rating Scales; Reboxetine; Selective Serotonin Reuptake Inhibitors; Severity of Illness Index; Treatment Outcome | 2010 |
Treatment effects of serotonergic and noradrenergic antidepressants on the intensity dependence of auditory ERP components in major depression.
Topics: Adrenergic Uptake Inhibitors; Adult; Antidepressive Agents; Citalopram; Depressive Disorder, Major; Evoked Potentials, Auditory; Female; Humans; Male; Middle Aged; Morpholines; Reboxetine; Selective Serotonin Reuptake Inhibitors | 2009 |
Are there differences between serotonergic, noradrenergic and dual acting antidepressants in the treatment of depressed women?
Topics: Adrenergic Uptake Inhibitors; Adult; Age Factors; Antidepressive Agents; Climacteric; Clinical Trials as Topic; Cyclohexanols; Depressive Disorder, Major; Drug Therapy, Combination; Female; Humans; Middle Aged; Morpholines; Personality Inventory; Reboxetine; Retrospective Studies; Selective Serotonin Reuptake Inhibitors; Sertraline; Venlafaxine Hydrochloride; Young Adult | 2009 |
Noradrenergic adverse effects due to combined treatment with reboxetine and triiodothyronine.
Topics: Adult; Depressive Disorder, Major; Drug Synergism; Drug Therapy, Combination; Humans; Male; Middle Aged; Morpholines; Norepinephrine; Reboxetine; Sleep Wake Disorders; Triiodothyronine; Young Adult | 2010 |
Finding studies on reboxetine: a tale of hide and seek.
Topics: Antidepressive Agents; Clinical Trials as Topic; Data Collection; Depressive Disorder, Major; Drug Approval; Humans; Morpholines; Publication Bias; Reboxetine; Research; Technology Assessment, Biomedical; United States; United States Food and Drug Administration | 2010 |
Natural killer cell cytotoxity and course of illness in depressed mood.
Topics: Adult; Antidepressive Agents; Cross-Sectional Studies; Cytotoxicity Tests, Immunologic; Depressive Disorder, Major; Dysthymic Disorder; Female; Humans; Interleukin-2; Interleukin-6; K562 Cells; Killer Cells, Natural; Male; Middle Aged; Morpholines; Pilot Projects; Reboxetine; Young Adult | 2010 |
Effects of reboxetine, a selective norepinephrine reuptake inhibitor, on sympathetic and parasympathetic outflow to the heart: preliminary data.
Topics: Adrenergic Uptake Inhibitors; Adult; Depressive Disorder, Major; Female; Heart; Heart Conduction System; Humans; Male; Middle Aged; Morpholines; Norepinephrine; Parasympathetic Fibers, Postganglionic; Reboxetine; Statistics, Nonparametric; Sympathetic Fibers, Postganglionic | 2002 |
Differential effects of reboxetine and citalopram on hand-motor function in patients suffering from major depression.
Topics: Acute Disease; Adrenergic Uptake Inhibitors; Adult; Biomechanical Phenomena; Citalopram; Depressive Disorder, Major; Dose-Response Relationship, Drug; Female; Hand; Handwriting; Humans; Male; Morpholines; Movement; Psychomotor Performance; Reboxetine; Selective Serotonin Reuptake Inhibitors | 2005 |
Sleepwalking associated with reboxetine in a young female patient with major depression--a case report.
Topics: Adolescent; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Female; Humans; Morpholines; Personality Inventory; Psychiatric Status Rating Scales; Reboxetine; Somnambulism | 2004 |
The intensity dependence of auditory evoked ERP components predicts responsiveness to reboxetine treatment in major depression.
Topics: Acoustic Stimulation; Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Radiation; Electrodes; Electroencephalography; Evoked Potentials, Auditory; Female; Humans; Male; Middle Aged; Morpholines; Predictive Value of Tests; Reboxetine; Statistics as Topic; Time Factors; Treatment Outcome | 2005 |
Asymptomatic reboxetine overdose.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Drug Overdose; Female; Humans; Morpholines; Reboxetine | 2006 |
Prediction of treatment response in major depression: integration of concepts.
Topics: Antidepressive Agents; Citalopram; Depressive Disorder, Major; Electroencephalography; Equipment Design; Evoked Potentials, Auditory; Female; Gyrus Cinguli; Humans; Male; Middle Aged; Morpholines; Neurophysiology; Prospective Studies; Reboxetine; Sleep Deprivation; Theta Rhythm | 2007 |
Reboxetine induced erectile dysfunction and spontaneous ejaculation during defecation and micturition.
Topics: Adult; Antidepressive Agents; Defecation; Depressive Disorder, Major; Humans; Male; Morpholines; Reboxetine; Sexual and Gender Disorders; Urination | 2007 |
Reboxetine combination in treatment-resistant depression to selective serotonin reuptake inhibitors.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Drug Resistance; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Male; Middle Aged; Morpholines; Prospective Studies; Psychiatric Status Rating Scales; Reboxetine; Selective Serotonin Reuptake Inhibitors | 2007 |
Reversal of trichotillomania with aripiprazole.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Depressive Disorder, Major; Drug Therapy, Combination; Female; Humans; Morpholines; Piperazines; Quinolones; Reboxetine; Self Concept; Sertraline; Social Adjustment; Trichotillomania | 2008 |
A case of non-SIADH-induced hyponatremia in depression after treatment with reboxetine.
Topics: Aged; Antidepressive Agents; Depressive Disorder, Major; Diagnosis, Differential; Dose-Response Relationship, Drug; Female; Humans; Hyponatremia; Inappropriate ADH Syndrome; Morpholines; Reboxetine; Recurrence; Sodium | 2009 |
Restless legs syndrome as side effect of second generation antidepressants.
Topics: Acute Disease; Adult; Antidepressive Agents; Citalopram; Depressive Disorder; Depressive Disorder, Major; Female; Humans; Male; Mianserin; Middle Aged; Mirtazapine; Morpholines; Prospective Studies; Reboxetine; Restless Legs Syndrome; Selective Serotonin Reuptake Inhibitors | 2008 |
Reboxetine in the treatment of depression in the elderly: pilot study.
Topics: Aged; Aged, 80 and over; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Dysthymic Disorder; Female; Humans; Morpholines; Personality Inventory; Pilot Projects; Reboxetine; Treatment Outcome | 1999 |
Reboxetine and treatment-refractory elderly patients with depression.
Topics: Aged; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Morpholines; Reboxetine | 2000 |
Urinary retention with reboxetine-fluoxetine combination in a young man.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Drug Therapy, Combination; Fluoxetine; Humans; Male; Morpholines; Reboxetine; Urinary Retention | 2000 |
Managing reboxetine-associated urinary hesitancy in a patient with major depressive disorder: a case study.
Topics: Adrenergic alpha-Antagonists; Adrenergic Uptake Inhibitors; Antidepressive Agents; Depressive Disorder, Major; Humans; Male; Middle Aged; Morpholines; Reboxetine; Sulfonamides; Tamsulosin; Urinary Retention | 2002 |